<DOC>
	<DOCNO>NCT00002192</DOCNO>
	<brief_summary>To determine antimicrobial activity tolerability rifapentine alone combination therapy patient AIDS disseminate Mycobacterium avium complex ( MAC ) bacteremia . To determine pharmacokinetics rifapentine metabolite , 25-desacetyl , alone combination therapy . To determine pharmacokinetics azithromycin clarithromycin ( 14-OH metabolite ) combination therapy .</brief_summary>
	<brief_title>Tolerance , Safety , Activity Rifapentine Alone Combination Therapy AIDS Patients With Mycobacterium Avium Complex Bacteremia .</brief_title>
	<detailed_description>This open-label , sequential study conduct two part : monotherapy phase combination treatment phase . In monotherapy phase sequential 3-patient cohort receive 1 3 dos rifapentine monotherapy . In combination treatment phase , 12 patient randomize one three arm : Arm I : Rifapentine ( assign dose level base monotherapy phase ) plus azithromycin . Arm II : Rifapentine ( assign dose level ) plus clarithromycin . Arm III : Rifapentine ( assign dose level ) plus ethambutol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented positive HIV serology status . Documented AIDS . Positive blood culture MAC studydesignated microbiology laboratory . NOTE : Patients presume MAC bacteremia , evidence positive blood , bone marrow , liver biopsy culture analyze locally , may enrol pending confirmation . Minimum two MACassociated symptom , define &gt; = grade 1 fever ; &gt; grade 1 night sweat , fatigue , diarrhea , abdominal pain , anorexia ; weight loss &gt; 5 % report within 4 week prior study entry . Life expectancy least 3 month . Prior Medication : Allowed : MAC prophylaxis medication study drug ( 5day washout period require ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Pulmonary tuberculosis . Infections require use disallow medication . Serious disease introduce undue risk adverse reaction study medication . Concurrent Medication : Excluded : Terfenadine . Treatment pulmonary TB . Study drug outside source . Medications antiMAC activity ( i.e. , amikacin , ciprofloxacin , clofazimine , rifampin , rifabutin ) . Patients follow prior condition exclude : History hypersensitivity rifabutin , rifampin , clarithromycin , erythromycin , azithromycin , ethambutol . Previous episode uveitis . Prior Medication : Excluded : Prophylactic treatment MAC rifabutin study medication . Azithromycin within 3 week prior randomization . Any investigational drug 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antitubercular Agents</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>rifapentine</keyword>
</DOC>